Avoiding misclassification of thrombotic primary antiphospholipid syndrome as systemic lupus erythematosus (SLE): What are the best-performing SLE classification criteria?

被引:6
作者
Signorelli, Flavio [1 ,2 ]
Balbi, Gustavo Guimaraes Moreira [1 ,3 ]
Bonfa, Eloisa [1 ]
Borba, Eduardo F. [1 ]
Andrade, Danieli Castro de Oliveira [1 ]
机构
[1] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Rheumatol Div, Av Dr Arnaldo 455,Third Floor,LIM 17, BR-01246903 Sao Paulo, SP, Brazil
[2] Univ Estado Rio De Janeiro, Hosp Univ Pedro Ernesto, Rheumatol Div, Rio De Janeiro, Brazil
[3] Univ Fed Juiz De Fora, Univ Hosp, Rheumatol Div, Juiz De Fora, Brazil
基金
巴西圣保罗研究基金会;
关键词
Systemic lupus erythematosus; primary antiphospholipid syndrome; ACR; EULAR 2019 criteria and SLICC 2012 criteria; ANTIBODIES; UPDATE;
D O I
10.1177/09612033211033978
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Systemic lupus erythematosus (SLE) and Primary Antiphospholipid Syndrome (PAPS) overlap clinical and immunological features. Therefore, misclassification of PAPS patients as SLE is a concern. The ACR/EULAR 2019 SLE classification has never been studied in PAPS. Objective To verify if the ACR/EULAR 2019 SLE classification can correctly classify a PAPS patient as not having SLE and compare its performance with the SLICC 2012 SLE classification. Methods: One-hundred thrombotic PAPS patients who fulfilled the Sidney criteria were consecutively screened and those who attended the inclusion criteria were submitted to ACR/EULAR 2019 and SLICC 2012 classifications. Results Sixty-seven PAPS patients were included in this study. The majority was female (89.6%) with median age at study inclusion of 45 years (35-53) and median PAPS disease duration of 13 years (8-19). PAPS correct classification was observed more often with ACR/EULAR 2019 than SLICC 2021 criteria (94.0% vs. 64.2%; p < 0.001). The 4 misclassified patients in ACR/EULAR 2019 were also misclassified in SLICC 2012. The comparison of misclassified patients to those correctly not classified as SLE resulted, for both criteria, in higher frequencies of hematological domain [ACR/EULAR 2019 (100% vs. 28.6%, p = 0.010) and SLICC 2012 (95.8% vs. 11.6%, p < 0.001)]. Further analysis of hematological manifestations revealed that for the ACR/EULAR 2019 leukopenia (100% vs. 22.2%, p = 0.004) and for the SLICC 2012 leukopenia/lymphopenia (91.7% vs. 7%, p < 0.001) were more frequent in misclassified group. Proteinuria (20.8% vs. 0%, p = 0.004) and low complement (45.8% vs. 20.9%, p = 0.033) were also more often observed in the incorrectly SLICC 2012 classified patients. Conclusion ACR/EULAR 2019 had high accuracy for distinguishing PAPS from SLE, whereas the SLICC 2012 incorrectly classified more than one third of the PAPS patients as having SLE.
引用
收藏
页码:1732 / 1738
页数:7
相关论文
共 16 条
  • [1] In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment
    Adamichou, Christina
    Nikolopoulos, Dionysis
    Genitsaridi, Irini
    Bortoluzzi, Alessandra
    Fanouriakis, Antonis
    Papastefanakis, Emmanouil
    Kalogiannaki, Eleni
    Gergianaki, Irini
    Sidiropoulos, Prodromos
    Boumpas, Dimitrios T.
    Bertsias, George K.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (02) : 232 - 241
  • [2] Development of autoantibodies before the clinical onset of systemic lupus erythematosus
    Arbuckle, MR
    McClain, MT
    Rubertone, MV
    Scofield, RH
    Dennis, GJ
    James, JA
    Harley, JB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (16) : 1526 - 1533
  • [3] Aringer M, 2019, ARTHRITIS RHEUMATOL, V71, P1400, DOI [10.1002/art.40930, 10.1136/annrheumdis-2018-214819]
  • [4] New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS
    Assan, Florence
    Seror, Raphaele
    Mariette, Xavier
    Nocturne, Gaetane
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (08)
  • [5] Comparison of Three Classification Criteria Sets for Systemic Lupus Erythematosus: A Study Looking at Links to Outcome and Mortality
    Carneiro, Antonio Costa
    Ruiz, Marta Mozo
    Freitas, Sara
    Isenberg, David
    [J]. ARTHRITIS CARE & RESEARCH, 2020, 72 (11) : 1611 - 1614
  • [6] Lessons from the "Euro-Phospholipid" project
    Cervera, Ricard
    [J]. AUTOIMMUNITY REVIEWS, 2008, 7 (03) : 174 - 178
  • [7] Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis Update of the guidelines for lupus anticoagulant detection and interpretation
    Devreese, Katrien M. J.
    de Groot, Philip G.
    de Laat, Bas
    Erkan, Doruk
    Favaloro, Emmanuel J.
    Mackie, Ian
    Martinuzzo, Marta
    Ortel, Thomas L.
    Pengo, Vittorio
    Rand, Jacob H.
    Tripodi, Armando
    Wahl, Denis
    Cohen, Hannah
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (11) : 2828 - 2839
  • [8] EHRENSTEIN MR, 1993, BRIT J RHEUMATOL, V32, P362
  • [9] Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
    Ginzler, EM
    Dooley, MA
    Aranow, C
    Kim, MY
    Buyon, J
    Merrill, JT
    Petri, M
    Gilkeson, GS
    Wallace, DJ
    Weisman, MH
    Appel, GB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (21) : 2219 - 2228
  • [10] Long-term follow-up in 128 patients with primary antiphospholipid syndrome -: Do they develop lupus?
    Gómez-Puerta, JA
    Martín, H
    Amigo, MC
    Aguirre, MA
    Camps, MT
    Cuadrado, MJ
    Hughes, GRV
    Khamashta, MA
    [J]. MEDICINE, 2005, 84 (04) : 225 - 230